

# John Kelton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9592841/publications.pdf>

Version: 2024-02-01

93  
papers

10,939  
citations

101543

36  
h-index

54911

84  
g-index

94  
all docs

94  
docs citations

94  
times ranked

4148  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S. <i>Blood Advances</i> , 2023, 7, 246-250.	5.2	18
2	SARS-CoV-2 spike-dependent platelet activation in COVID-19 vaccine-induced thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 2250-2253.	5.2	10
3	The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 4228-4235.	5.2	18
4	A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1096-1102.	3.8	10
5	Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1342-1347.	3.8	74
6	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. <i>Viruses</i> , 2021, 13, 697.	3.3	36
7	Performance characteristics of platelet autoantibody testing for the diagnosis of immune thrombocytopenia using strict clinical criteria. <i>British Journal of Haematology</i> , 2021, 194, 439-443.	2.5	5
8	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	3.8	14
9	Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia. <i>Nature</i> , 2021, 596, 565-569.	27.8	218
10	Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>New England Journal of Medicine</i> , 2021, 385, 720-728.	27.0	156
11	Platelet variability index: a measure of platelet count fluctuations in patients with immune thrombocytopenia. <i>Blood Advances</i> , 2021, 5, 4256-4264.	5.2	4
12	Lessons from vaccine-induced immune thrombotic thrombocytopenia. <i>Nature Reviews Immunology</i> , 2021, 21, 753-755.	22.7	27
13	Increased cytotoxic potential of CD8 <sup>+</sup> T cells in immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 188, e72-e76.	2.5	11
14	Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial. <i>Lancet Haematology</i> , 2020, 7, e640-e648.	4.6	16
15	The role of fluid-phase immune complexes in the pathogenesis of heparin-induced thrombocytopenia. <i>Thrombosis Research</i> , 2020, 194, 135-141.	1.7	5
16	A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. <i>Platelets</i> , 2019, 30, 1017-1021.	2.3	6
17	The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 787-794.	3.8	51
18	Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 389-399.	3.8	33

#	ARTICLE	IF	CITATIONS
19	Platelet-Activating Antibodies Are Detectable at the Earliest Onset of Heparin-Induced Thrombocytopenia, With Implications for the Operating Characteristics of the Serotonin-Release Assay. <i>Chest</i> , 2018, 153, 1396-1404.	0.8	16
20	Autoantibodies to thrombopoietin and the thrombopoietin receptor in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 234-241.	2.5	21
21	Development of a high-yield expression and purification system for platelet factor 4. <i>Platelets</i> , 2018, 29, 249-256.	2.3	18
22	How do we diagnose immune thrombocytopenia in 2018?. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 561-567.	2.5	25
23	Megakaryocyte apoptosis in immune thrombocytopenia. <i>Platelets</i> , 2018, 29, 729-732.	2.3	24
24	The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2017, 178, 302-307.	2.5	32
25	Producing megakaryocytes from a human peripheral blood source. <i>Transfusion</i> , 2016, 56, 1066-1074.	1.6	12
26	High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. <i>Lancet Haematology</i> , 2016, 3, e489-e496.	4.6	131
27	Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. <i>Transfusion</i> , 2016, 56, 73-79.	1.6	8
28	Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. <i>Blood</i> , 2016, 128, 2548-2548.	1.4	1
29	Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. <i>Lancet Haematology</i> , 2015, 2, e75-e81.	4.6	99
30	Antibody binding to megakaryocytes <i>in vivo</i> in patients with immune thrombocytopenia. <i>European Journal of Haematology</i> , 2015, 95, 532-537.	2.2	10
31	The platelet serotonin release assay. <i>American Journal of Hematology</i> , 2015, 90, 564-572.	4.1	138
32	Pitfalls in the diagnosis of heparin-induced thrombocytopenia: A 6-year experience from a reference laboratory. <i>American Journal of Hematology</i> , 2015, 90, 629-633.	4.1	26
33	A phase II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. <i>British Journal of Haematology</i> , 2015, 170, 208-217.	2.5	31
34	Novel treatments for immune thrombocytopenia. <i>Presse Medicale</i> , 2014, 43, e87-e95.	1.9	21
35	Nonheparin Anticoagulants for Heparin-Induced Thrombocytopenia. <i>New England Journal of Medicine</i> , 2013, 368, 737-744.	27.0	107
36	Persistent Impairments in Humoral and Cellular Immunity in Patients with Immune Thrombocytopenia Treated with Rituximab: A Sub-Study of a Randomized Controlled Trial. <i>Blood</i> , 2012, 120, 492-492.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Prevalence and Risk of Preexisting Heparin-Induced Thrombocytopenia Antibodies in Patients With Acute VTE. <i>Chest</i> , 2011, 140, 366-373.	0.8	69
38	Identifying Drugs Implicated in Drug-Induced Immune Thrombocytopenia Using Levels of Evidence Applied to Laboratory Tests. <i>Blood</i> , 2011, 118, 3304-3304.	1.4	0
39	The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia. <i>Blood</i> , 2010, 116, 3691-3691.	1.4	0
40	Understanding Treatment Preferences In Patients with Primary Immune Thrombocytopenia Contemplating Splenectomy: A Qualitative Study. <i>Blood</i> , 2010, 116, 392-392.	1.4	0
41	A Spontaneous Prothrombotic Disorder Resembling Heparin-induced Thrombocytopenia. <i>American Journal of Medicine</i> , 2008, 121, 632-636.	1.5	154
42	Heparin-induced thrombocytopenia: a historical perspective. <i>Blood</i> , 2008, 112, 2607-2616.	1.4	172
43	Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 471-475.	1.0	21
44	Incidence of HPA-9b in Testing for Neonatal Alloimmune Thrombocytopenia. <i>Blood</i> , 2007, 110, 3214-3214.	1.4	0
45	Peripartum Management of Women with Suspected Hereditary Thrombocytopenia. <i>Blood</i> , 2007, 110, 3224-3224.	1.4	0
46	An Individual Platelet Count Set-Point in ITP: A Concept Learned from Patients with Mild Thrombocytopenia and a Good Response to IVIg or Corticosteroids. <i>Blood</i> , 2007, 110, 3926-3926.	1.4	0
47	An Algorithm for "Indeterminate" Test Results in the Platelet Serotonin Release Assay for Heparin-Induced Thrombocytopenia (HIT). <i>Blood</i> , 2006, 108, 1048-1048.	1.4	0
48	The Pathophysiology of Heparin-Induced Thrombocytopenia. <i>Chest</i> , 2005, 127, 9S-20S.	0.8	96
49	Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. <i>Blood</i> , 2005, 106, 3791-3796.	1.4	271
50	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need?. <i>Translational Research</i> , 2005, 146, 341-346.	2.3	261
51	Heparin-Induced Thrombocytopenia: An Iceberg Rising. <i>Mayo Clinic Proceedings</i> , 2005, 80, 988-990.	3.0	19
52	Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2004, 77, 387-390.	4.1	19
53	Treatment of Heparin-Induced Thrombocytopenia. <i>Archives of Internal Medicine</i> , 2004, 164, 361.	3.8	184
54	An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients. <i>Archives of Internal Medicine</i> , 2003, 163, 2518.	3.8	287

#	ARTICLE	IF	CITATIONS
55	Argatroban Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Archives of Internal Medicine, 2003, 163, 1849.	3.8	396
56	Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: will recent insight into pathogenesis translate into better treatment?. Transfusion, 2002, 42, 388-392.	1.6	18
57	Immune-mediated thrombocytopenia. , 2002, , 542-555.		0
58	Temporal Aspects of Heparin-Induced Thrombocytopenia. New England Journal of Medicine, 2001, 344, 1286-1292.	27.0	925
59	Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 2001, 98, 1842-1846.	1.4	198
60	Delayed-Onset Heparin-Induced Thrombocytopenia and Thrombosis. Annals of Internal Medicine, 2001, 135, 502.	3.9	429
61	Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood, 2000, 96, 188-194.	1.4	190
62	Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood, 2000, 96, 1703-1708.	1.4	976
63	Measurement of endogenous and exogenous alpha $\alpha$ -granular platelet proteins in patients with immune and nonimmune thrombocytopenia. British Journal of Haematology, 1999, 106, 762-770.	2.5	5
64	Laboratory abnormalities in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1998, 103, 1031-1036.	2.5	55
65	Factor V Leiden and Thrombotic Complications in Heparin-induced Thrombocytopenia. Thrombosis and Haemostasis, 1998, 79, 50-53.	3.4	37
66	PROTEOLYTIC DEGRADATION OF HIGH MOLECULAR WEIGHT KININOGEN IN ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA. British Journal of Haematology, 1997, 97, 762-767.	2.5	5
67	A 14-year study of heparin-induced thrombocytopenia. American Journal of Medicine, 1996, 101, 502-507.	1.5	872
68	Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1996, 93, 421-426.	2.5	18
69	The epitope specificity of heparin-induced thrombocytopenia. British Journal of Haematology, 1996, 95, 161-167.	2.5	152
70	A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. British Journal of Haematology, 1996, 95, 724-731.	2.5	125
71	Bacterial infection-associated improvement of platelet counts in two patients with chronic and unresponsive idiopathic thrombocytopenic purpura with normal platelet survival studies. British Journal of Haematology, 1995, 90, 332-335.	2.5	5
72	The prenatal identification of fetal compatibility in neonatal alloimmune thrombocytopenia using amniotic fluid and variable number of tandem repeat (VNTR) analysis. British Journal of Haematology, 1995, 91, 742-746.	2.5	17

#	ARTICLE	IF	CITATIONS
73	A prospective study to determine the frequency and clinical significance of alloimmunization postâ€transfusion. British Journal of Haematology, 1995, 91, 1000-1005.	2.5	159
74	The use of antiâ€D to improve postâ€transfusion platelet response: a randomized trial. British Journal of Haematology, 1995, 89, 163-168.	2.5	11
75	Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin. New England Journal of Medicine, 1995, 332, 1330-1336.	27.0	2,664
76	The Serological Investigation of Patients with Autoimmune Thrombocytopenia. Thrombosis and Haemostasis, 1995, 74, 228-233.	3.4	35
77	Heparinâ€induced thrombocytopenia and thrombosis: clinical and laboratory studies. British Journal of Haematology, 1993, 84, 322-328.	2.5	175
78	PATHOPHYSIOLOGY OF HEPARINâ€INDUCED THROMBOCYTOPENIA. British Journal of Haematology, 1992, 82, 778-779.	2.5	3
79	HLAâ€DR expression by platelets in acute idiopathic thrombocytopenic purpura. British Journal of Haematology, 1992, 81, 552-557.	2.5	33
80	A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing. British Journal of Haematology, 1992, 81, 579-584.	2.5	42
81	Immune haemolytic anaemia and thrombocytopenia: drugs and autoantibodies. Biochemical Society Transactions, 1991, 19, 183-186.	3.4	5
82	Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1990, 74, 457-464.	2.5	71
83	Alloimmune neonatal thrombocytopenia associated with incidental maternal thrombocytopenia. American Journal of Hematology, 1990, 35, 43-44.	4.1	15
84	Current Concepts in the Treatment of Immune Thrombocytopenia. Drugs, 1990, 40, 531-542.	10.9	18
85	A prospective comparison of four techniques for measuring plateletâ€associated IgG. British Journal of Haematology, 1989, 71, 97-105.	2.5	55
86	Neonatal alloimmune thrombocytopenia: Spontaneous in utero intracranial hemorrhage. American Journal of Hematology, 1988, 28, 98-102.	4.1	46
87	Platelet IgG Fc receptor. American Journal of Hematology, 1987, 25, 299-310.	4.1	39
88	Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura. British Journal of Haematology, 1987, 66, 509-513.	2.5	26
89	PLATELET AUTOANTIBODIES IN SEPTICAEMIA. British Journal of Haematology, 1985, 61, 589-591.	2.5	1
90	Platelet fragments do not contribute to elevated levels of platelet associated IgG. British Journal of Haematology, 1985, 61, 707-715.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Comparison of the measurement of surface or total platelet-associated IgG in the diagnosis of immune thrombocytopenia. American Journal of Hematology, 1985, 18, 1-5.	4.1	21
92	Studies on the frequency of heparin-associated thrombocytopenia. Thrombosis Research, 1984, 33, 439-443.	1.7	80
93	Quantitation of red cell membrane associated immunoglobulin in children with Plasmodium falciparum parasitaemia. British Journal of Haematology, 1983, 54, 567-572.	2.5	22